Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour

Singapore Medical Journal

Volumn 48, Issue 1, 2007, Pages

  Durosinmi, Muheez A ^a   Ogbe, P O ^b   Salawu, L ^a   Oyekunle, A A ^a  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^b NATIONAL HOSPITAL   (Nigeria)

Author keywords

Gastrointestinal stromal tumour; Herpes zoster; Imatinib mesylate; Varicella zoster virus

Indexed keywords

ACICLOVIR; ANALGESIC AGENT; BCR ABL PROTEIN; CD4 ANTIGEN; IMATINIB; STEM CELL FACTOR RECEPTOR; ANTIVIRUS AGENT; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER PATIENT; CASE REPORT; CD4 LYMPHOCYTE COUNT; CHRONIC MYELOID LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; HERPES ZOSTER; HUMAN; LYMPHOCYTE COUNT; MALE; NIGERIA; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND DRESSING; BANDAGE; DIFFERENTIAL DIAGNOSIS; DRUG ANTAGONISM; MIDDLE AGED;

ACYCLOVIR; ANTIVIRAL AGENTS; BANDAGES; DIAGNOSIS, DIFFERENTIAL; GASTROINTESTINAL STROMAL TUMORS; HERPES ZOSTER; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 33846952155     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7:705-12.
2. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001; 32:578-82.
3. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16:566-78.
4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813-25.
5. Maertens O, Prenen H, Debiec-Rychter M, et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 2006; 15:1015-23.
6. Ceballos KM, Francis JA, Mazurka JL. Gastrointestinal stromal tumor presenting as a recurrent vaginal mass. Arch Pathol Lab Med 2004; 128:1442-4.
7. Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13:577-85.
8. Nakagawa M, Akasaka Y, Kanai T, et al. Extragastrointestinal stromal tumor of the greater omentum: case report and review of the literature. Hepatogastroenterology 2003; 50:691-5.
9. Dereure O. Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies. Expert Opin Drug Saf 2003; 2:467-73.
10. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-42. Erratum in: N Eng J Med 2001; 345:232.
11. Comment in: N Engl J Med 2001; 344:1084-6.
12. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
13. Comment in: Clin Lab Haematol 2005; 27: 416-7,
14. Curr Hematol Rep 2004; 3:37-8,
15. N Engl J Med 2003; 348:1048-50.
16. Drummond A, Micallef-Eynaud P, Douglas WS, et al. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI571, Glivec). Br J Haematol 2003; 120:911-3.
17. Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48:201-6.
18. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006; 5:228-31.
19. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
20. Comment in: N Engl J Med 2001; 344: 1084-6,
21. N Engl J Med 2001; 345: 618-9.
22. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase 1 study. Lancet 2001; 358:1421-23.
23. Comment in: Lancet 2001; 358 : 1903.
24. Bergeron A, Bergot E, Vilela G, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol 2002; 20:4271-2.
25. Brazzelli V, Prestinari F, Roveda E, et al. Pityriasis rosea-like eruption during treatment with imatinib mesylate:description of 3 cases. J Am Acad Dermatol 2005; 53(5 Suppl 1):S240-3.
26. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98:2483-7.
27. Comment in: Cancer 2004; 100:2486-7; author reply 2487-8.
28. Brazzelli V, Roveda E, Prestinari F, et al. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment. Pediatr Dermatol 2006; 23:175-8.
29. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med 2001; 345:618-9.
30. Comment on: N Engl J Med 2001; 344:1031-7.
31. Schwarz M, Kreuzer KA, Baskaynak G, Dörken B, le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002: 69:254-6.
32. Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002; 117:620-2.
33. Clark SH, Duvic M, Prieto VG. Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol 2003; 30:279-81.
34. Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003; 9:976-80.
35. Whitley RJ. Varicella-zoster virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Edinburgh: Churchill Livingstone, 2002: 1580-6.
36. Rusthoven JJ, Ahlgren P, Elhakim T, et al. Varicella-zoster infection in adult cancer patients. A population study. Arch Intern Med 1988; 148:1561-6.
37. Mazur MH, Dolin R. Herpes zoster at the NIH: a 20 year experience. Am J Med 1978; 65:738-44.
38. Goffinet DR, Glatstein EJ, Merigan TC. Herpes Zoster-Varicella infections and lymphoma. Ann Int Med 1972; 76:235-40.
39. Dietz AB, Souan L, Knutson GJ, et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104:1094-9.